Continuous subcutaneous lisuride infusion in OPCA.
Four patients with sporadic olivopontocerebellar atrophy (OPCA) and severe signs of Parkinsonism received continuous subcutaneous lisuride infusion via a small external pump. All 4 patients benefitted from this treatment: 3 showed an overall improvement in motor performance, in 1 patient mainly dysphagia and dysarthria improved. Therapeutic benefit lasted for at least 6 months of follow up. With a daily dose of 1.0 mg subcutaneous lisuride, treatment limitations were reached in the form of dysphagia, probably due to oropharyngeal dystonia. Subcutaneous lisuride infusion should be taken into consideration in OPCA patients with signs of Parkinsonism if oral dopaminergic treatment has failed earlier on.
Heinz
A
A
Department of Neurology, St. Josef Hospital, Ruhr University, Bochum, Federal Republic of Germany.
Wöhrle
J
J
Schöls
L
L
Klotz
P
P
Kuhn
W
W
Przuntek
H
H
D000368:Aged; D003680:Deglutition Disorders / Q000139:chemically induced; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008090:Lisuride / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009849:Olivopontocerebellar Atrophies / Q000188:drug therapy*; D011605:Psychoses, Substance-Induced; D016896:Treatment Outcome
D008090:Lisuride